Skip to main content

Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC)

Publication ,  Conference
Nelson, JB; Fizazi, K; Miller, K; Higano, CS; Moul, JW; Morris, T; McIntosh, S; Pemberton, K; Gleave, ME
Published in: JOURNAL OF CLINICAL ONCOLOGY
March 1, 2011

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

March 1, 2011

Volume

29

Issue

7

Publisher

AMER SOC CLINICAL ONCOLOGY

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nelson, J. B., Fizazi, K., Miller, K., Higano, C. S., Moul, J. W., Morris, T., … Gleave, M. E. (2011). Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 29). AMER SOC CLINICAL ONCOLOGY.
Nelson, J. B., K. Fizazi, K. Miller, C. S. Higano, J. W. Moul, T. Morris, S. McIntosh, K. Pemberton, and M. E. Gleave. “Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 29. AMER SOC CLINICAL ONCOLOGY, 2011.
Nelson JB, Fizazi K, Miller K, Higano CS, Moul JW, Morris T, et al. Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2011.
Nelson, J. B., et al. “Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 29, no. 7, AMER SOC CLINICAL ONCOLOGY, 2011.
Nelson JB, Fizazi K, Miller K, Higano CS, Moul JW, Morris T, McIntosh S, Pemberton K, Gleave ME. Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2011.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

March 1, 2011

Volume

29

Issue

7

Publisher

AMER SOC CLINICAL ONCOLOGY

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences